Schroder Investment Management Group’s Travere Therapeutics TVTX Stock Holding History

Schroder Investment Management Group’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$22.1M	Buy	379,611 +164,686	+77%	+$7.3M	0.02%	527
2026 Q1	$5.94M	Buy	+214,925	New	+$6.42M	﹤0.01%	750
2025 Q4	–	Sell	-62,293	Closed	-$1.5M	–	1213
2025 Q3	$1.5M	Sell	62,293 -358,219	-85%	-$6.73M	﹤0.01%	976
2025 Q2	$6.22M	Sell	420,512 -172,512	-29%	-$2.86M	0.01%	732
2025 Q1	$11.7M	Buy	593,024 +175,771	+42%	+$3.57M	0.01%	612
2024 Q4	$7.23M	Sell	417,253 -260,199	-38%	-$4.6M	0.01%	706
2024 Q3	$9.49M	Buy	677,452 +43,051	+7%	+$449K	0.01%	671
2024 Q2	$5.21M	Buy	634,401 +530,024	+508%	+$3.57M	0.01%	774
2024 Q1	$805K	Buy	+104,377	New	+$881K	﹤0.01%	1055

Other funds holding TVTX

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Schroder Investment Management Group's TVTX Position: Q2 2026 in Review

Schroder Investment Management Group increased its Travere Therapeutics (TVTX) stake by 77% in Q2 2026, buying an estimated $7.3M and bringing the position to 379,611 shares worth $22.1M. The position accounts for 0.02% of the portfolio, ranked #527.

Schroder Investment Management Group first reported a position in TVTX in Q1 2024 and has held it in 9 quarters since. 320 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

Schroder Investment Management Group held 379,611 shares of Travere Therapeutics worth $22.1M as of Q2 2026.
Schroder Investment Management Group bought 164,686 Travere Therapeutics shares in Q2 2026, an estimated $7.3M.
Travere Therapeutics made up 0.02% of Schroder Investment Management Group's portfolio in Q2 2026, its #527 holding.
Schroder Investment Management Group first reported a position in Travere Therapeutics in Q1 2024 and has held it in 9 quarters since.
320 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Schroder Investment Management Group's 13F filing for Q2 2026, filed 13 Aug 2026.